HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
- DOI
- 10.1038/s41467-024-53223-3
- Published
- 2024 Nov 25
- Container
- Nature communications
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41467-024-53223-3,
title = {HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.},
author = {Siena S and Raghav K and Masuishi T and Yamaguchi K and Nishina T and Elez E and Rodriguez J and Chau I and Di Bartolomeo M and Kawakami H and Suto F and Koga M and Inaki K and Kuwahara Y and Takehara I and Barrios D and Kobayashi K and Grothey A and Yoshino T},
year = {2024},
journal = {Nature communications},
doi = {10.1038/s41467-024-53223-3},
url = {https://doi.org/10.1038/s41467-024-53223-3}
}RIS
TY - JOUR TI - HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. AU - Siena S AU - Raghav K AU - Masuishi T AU - Yamaguchi K AU - Nishina T AU - Elez E AU - Rodriguez J AU - Chau I AU - Di Bartolomeo M AU - Kawakami H AU - Suto F AU - Koga M AU - Inaki K AU - Kuwahara Y AU - Takehara I AU - Barrios D AU - Kobayashi K AU - Grothey A AU - Yoshino T PY - 2024 JO - Nature communications DO - 10.1038/s41467-024-53223-3 UR - https://doi.org/10.1038/s41467-024-53223-3 ER -
APA
S, S., K, R., T, M., K, Y., T, N., E, E., J, R., I, C., M, D. B., H, K., F, S., M, K., K, I., Y, K., I, T., D, B., K, K., A, G., & T, Y. (2024). HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.. Nature communications. https://doi.org/10.1038/s41467-024-53223-3
Source records
- pubmed · retrieved 2026-09-26T18:00:35.382Z
- europe-pmc · retrieved 2026-09-26T18:00:35.395Z